Nature Medicine, Published online: 10 May 2026; doi:10.1038/s41591-026-04406-6
As presented at the 2026 ESC Heart Failure Congress, in a large randomized controlled trial in patients with heart failure with reduced or mildly reduced ejection fraction, treatment with low-dose digoxin was generally safe and well tolerated, but did not significantly reduce the composite endpoint of total worsening heart failure events or cardiovascular mortality.
